KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

NCT04640532 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis
Post-PV MF
Post-ET Myelofibrosis
Primary Myelofibrosis

Interventions

DRUG: KRT-232
DRUG: TL-895

Sponsor

Kartos Therapeutics, Inc.

Collaborators

[object Object]